Nutramax to form expert panel to improve G/C guidelines
EDGEWOOD, Md. — Nutramax Laboratories Consumer Care on Tuesday announced plans to assemble a panel of joint health experts to review current American Academy of Orthopaedic Surgeons guidance on the use of glucosamine/chondroitin sulfate supplements for joint health. The panel will focus specifically on the most recent AAOS Evidence-based Guideline for using joint health supplements and provide its recommendation based on a growing body of clinical evidence.
"The very positive results from recent trials of glucosamine and chondroitin sulfate support our published research from 1999 and 2000," stated Robert Henderson, chairman Nutramax Laboratories. "In light of those results, it is time to start a dialog with the AAOS to review the accumulated clinical evidence regarding the combined use of glucosamine and chondroitin sulfate for joint health."
Recently published randomized, controlled trials using high-quality, pharmaceutical-grade glucosamine and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, have produced very positive outcomes for patient populations in the studies.
Under the guidance of Brian Cornblatt, medical director of Nutramax Laboratories, the panel of experts will review the available clinical evidence supporting the use of glucosamine/chondroitin sulfate supplementation in promoting joint health, and work with the AAOS guideline committee to explore consideration of this evidence in the third edition of the Evidence-based Guideline. The members of the task force will focus special attention on the following recent publications:
- MOVES (Multicentre Osteoarthritis InterVEntion trial with Sysadoa): This study provides the most recent evidence to support the use of glucosamine hydrochloride and chondroitin sulfate, at a daily dose of 1,500 and 1,200 milligrams, respectively, in managing joint health in a wide variety of patient populations. The results were published in January 2015 in the online edition of Annals of the Rheumatic Diseases;
- GAIT (Glucosamine/Chondroitin Arthritis Intervention Trial): Published in The New England Journal of Medicine in 2006, the GAIT study showed that glucosamine hydrochloride and chondroitin sulfate, at the same daily dose as used in the MOVES trial, may be a viable option in a subgroup of patients with moderate to severe joint discomfort. The MOVES study was developed as an extension of the GAIT study;
- Brazilian Trial (Prospective, Multi-Center, Randomized Controlled Trial): In an international, head-to-head study involving more than 900 participants, a team of Brazilian researchers found that Nutramax Laboratories' CosaminDS, which contains 1,500 mg of glucosamine hydrochloride and 1,200 mg of chondroitin sulfate in capsule form, and a Brazilian prescription brand containing the same doses of these ingredients either as a sachet or a capsule formulation, were equally effective. The researchers, who published their results in Clinical Rheumatology in August 2014, reported statistically significant improvements in joint comfort and physical function as measured by change from baseline using a visual analog scale and the Lequesne Index, a measure of osteoarthritis severity. They also observed no significant alterations in laboratory values assessing safety, including fasting glycemia; and
- Cochrane Review: In a review published in January 2015, the Cochrane Collaborative characterized chondroitin sulfate as more effective than placebo in improving pain and physical function in patients with osteoarthritis, with a lower risk of adverse events. The Cochrane review – the most comprehensive review of chondroitin sulfate published to date – examined data from 43 randomized, controlled, short-term trials involving 4,962 participants treated with chondroitin sulfate and 4,148 participants who were given a placebo or another control, and concluded that the benefit of chondroitin sulfate in these studies was clinically meaningful.
"Our aim is to explore whether current guidelines accurately reflect real-world experience and recent clinical evidence supporting the use of high-quality glucosamine and chondroitin to support joint health," said Nicholas DiNubile, an orthopedic surgeon. "It is important that we open discussions with our colleagues about the role of supplements and to achieve a better understanding of when and where high-quality supplements fit into the overall joint health management paradigm."
Durex synchs app launch to Earth Hour
BY DSN STAFF
PARSIPPANY, N.J. — Durex on Monday revealed today the final chapter of its 'Durex Connect' campaign by releasing a smartphone app that helps people do exactly that, just in time for Earth Hour.
After teasing a technology breakthrough that could revolutionize our sex lives, a viral video (above) was released by Durex that quickly grew to be viewed by over 40 million people around the world. The video showed tech-obsessed couples' reactions to the revelation that the bedroom miracle they needed was simply the off-button. Following this international response, Durex developed an app that offers a simple solution: synchronizing a couple's phones to sleep together.
"The 'Durex Connect' film followed the couples who volunteered on an emotional and reflective journey where they came to terms with their true obsession with technology in their relationships, and the campaign has really highlighted this on a global scale," said Ukonwa Ojo, head of global brand equity at Durex. "The large number of people visiting the Durexlabs sign-up page really helped us truly understand the app needs of our consumers. As we approach Earth Hour on March 28 from 8:30 p.m. – 9:30 p.m., we invite couples around the world to discover this new Durex app."
The 'Durex Connect' app, available for free download on Android and soon to be out on iOS, is a user-friendly way to synchronize a smartphone with a person's partner, so that neither can renege on the promise of dedicated, tech-free connection. At agreed times, or by spontaneous agreement, it will simply mask the phones' home screen, effectively putting the handsets to sleep and removing all distractions.
Study: Vitamin D helps maintain bone density
CHICAGO — In a clinical trial that explored the effectiveness of exercise training and vitamin D supplementation for reducing falls in older women, neither intervention affected the overall rate of falls, according to an article published online Monday by JAMA Internal Medicine. However, vitamin D did help to maintain bone density in the femoral neck (a segment of the femur most likely to break with osteoporosis) and increased tibial trabecular density in the shinbone.
Only exercise improved muscle strength and balance, while vitamin D did not enhance the effects of exercise on physical functioning.
“Given the fact that fall risk is multifactorial, exercise may be the most effective and feasible strategy for preventing injurious falls in community-dwelling older adults replete with vitamin D," said Kirsti Uusi-Rasi, researcher with the UKK Institute for Health Promotion Research, Tampere, Finland. "Herein, vitamin D increased bone density slightly, and exercise improved physical functioning. While neither treatment reduced the rate of falling, injurious falls more than halved among exercisers with or without vitamin D. Our participants were vitamin D replete, with sufficient calcium intake. Future research is needed to elaborate the role of vitamin D to enhance physical functioning in elderly women.”
"This new study confirms the established role of vitamin D for bone health, but there are many other beneficial reasons for people to supplement with vitamin D," said Duffy MacKay, SVP scientific and regulatory affairs for the Council for Responsible Nutrition. "Other studies have pointed to a role for vitamin D in helping with cognitive function and reducing the risk of heart disease, diabetes and other chronic diseases; however, it is important to manage expectations for vitamin D’s role in isolation and to remember that optimal nutrition is just one component of many needed to prevent chronic disease."
Falls are the leading cause of unintentional injuries and fractures in older adults. However, reviews of clinical trials on the role of vitamin D in reducing falls and fractures in community-dwelling older adults and in improving physical functioning have been inconclusive, according to the study background.
In an accompanying commentary to the study, the commentary authors noted that although this new study didn’t find benefit for vitamin D in preventing falls among older women, updating the recent USPSTF meta-analysis to include this trial " … does not change the overall conclusion that vitamin D remains associated with an 11% decreased risk of falls."
The authors pointed to some of the possible confounding factors to consider with this positive conclusion for vitamin D, including whether calcium was also administered. Further, the commentary authors reminded doctors that given its low cost and low risk, vitamin D should remain in the physician’s collection of resources while more research continues. "As those authors pointed out, taking a person’s vitamin D status into account may be useful in determining recommendations for helping prevent falls," MacKay said.
Loading Post Please Wait...